US Edition
Published • loading... • Updated
Making a MASH Hit: PNPLA3 and the Rise of Genotype-Driven Therapies
Summary by Drug Hunter
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Making a MASH Hit: PNPLA3 and the Rise of Genotype-Driven Therapies
The rise of GLP-1R agonists and the recent approval of semaglutide for MASH have reignited interest in drug targets for severe liver diseases. MASH remains one of the most unforgiving indications in the clinic; multiple mechanisms with promising preclinical biology—including FGF21, DGAT2, HSD17B13, PPAR agonism, among others—have led to disappointing clinical outcomes. Against this background, an important question must be asked: beyond metaboli…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
